This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Jan 1;191(1):110-3.

doi: 10.1164/rccm.201406-1106LE.

Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis

Benjamin Loeh¹, Fotios Drakopanagiotakis, Gian Piero Bandelli, Daniel von der Beck, Silke Tello, Elisa Cordani, Elvira Rizza, Laura Barrocu, Philipp Markart, Werner Seeger, Andreas Guenther, Carlo Albera

Affiliations

PMID: 25551350
DOI: 10.1164/rccm.201406-1106LE

Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis

Benjamin Loeh et al. Am J Respir Crit Care Med. 2015.

. 2015 Jan 1;191(1):110-3.

doi: 10.1164/rccm.201406-1106LE.

Authors

Benjamin Loeh¹, Fotios Drakopanagiotakis, Gian Piero Bandelli, Daniel von der Beck, Silke Tello, Elisa Cordani, Elvira Rizza, Laura Barrocu, Philipp Markart, Werner Seeger, Andreas Guenther, Carlo Albera

Affiliation

¹ 1 Agaplesion Pneumologische Klinik Waldhof-Elgershausen Greifenstein, Germany.

PMID: 25551350
DOI: 10.1164/rccm.201406-1106LE

No abstract available

PubMed Disclaimer

Similar articles

Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Chaudhuri N, et al. Respir Med. 2014 Jan;108(1):224-6. doi: 10.1016/j.rmed.2013.11.005. Epub 2013 Nov 15. Respir Med. 2014. PMID: 24269005
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Noble PW, et al. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. Lancet. 2011. PMID: 21571362 Clinical Trial.
Pirfenidone for idiopathic pulmonary fibrosis.
Bouros D. Bouros D. Lancet. 2011 May 21;377(9779):1727-9. doi: 10.1016/S0140-6736(11)60546-1. Epub 2011 May 13. Lancet. 2011. PMID: 21571363 No abstract available.
Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A. Azuma A. Ther Adv Respir Dis. 2012 Apr;6(2):107-14. doi: 10.1177/1753465812436663. Epub 2012 Feb 14. Ther Adv Respir Dis. 2012. PMID: 22333982 Review.
[Antifibrotic treatment].
von der Beck D, Löh B, Drakopanagiotakis F, Markart P, Günther A. von der Beck D, et al. Dtsch Med Wochenschr. 2014 Dec;139(49):2523-5. doi: 10.1055/s-0034-1387450. Epub 2014 Nov 25. Dtsch Med Wochenschr. 2014. PMID: 25423462 Review. German. No abstract available.

See all similar articles

Cited by

Idiopathic pulmonary fibrosis: pathogenesis and management.
Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Sgalla G, et al. Respir Res. 2018 Feb 22;19(1):32. doi: 10.1186/s12931-018-0730-2. Respir Res. 2018. PMID: 29471816 Free PMC article. Review.
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Lancaster LH, et al. Eur Respir Rev. 2017 Dec 6;26(146):170057. doi: 10.1183/16000617.0057-2017. Print 2017 Dec 31. Eur Respir Rev. 2017. PMID: 29212837 Free PMC article. Review.
Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.
Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D. Tzouvelekis A, et al. Front Med (Lausanne). 2017 Nov 29;4:213. doi: 10.3389/fmed.2017.00213. eCollection 2017. Front Med (Lausanne). 2017. PMID: 29238708 Free PMC article.
Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use.
Lyseng-Williamson KA. Lyseng-Williamson KA. Drugs Ther Perspect. 2018;34(1):8-15. doi: 10.1007/s40267-017-0459-x. Epub 2017 Nov 14. Drugs Ther Perspect. 2018. PMID: 30008572 Free PMC article.
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.
Biondini D, Balestro E, Lacedonia D, Cerri S, Milaneschi R, Luppi F, Cocconcelli E, Bazzan E, Clini E, Foschino Barbaro MP, Gregori D, Cosio MG, Saetta M, Spagnolo P. Biondini D, et al. Sci Rep. 2018 Apr 13;8(1):5961. doi: 10.1038/s41598-018-24303-4. Sci Rep. 2018. PMID: 29654244 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- ClinicalTrials.gov